Abnormal subcellular localization of GABAA receptor subunits in schizophrenia brain
Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA A R). In schizophrenia, presynaptic GABAergic signaling deficits are among the most replicated findings; however, postsynaptic GABAergic deficits are less well characteriz...
Saved in:
Published in | Translational psychiatry Vol. 5; no. 8; p. e612 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
04.08.2015
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA
A
R). In schizophrenia, presynaptic GABAergic signaling deficits are among the most replicated findings; however, postsynaptic GABAergic deficits are less well characterized. Our lab has previously demonstrated that although there is no difference in total protein expression of the α1–6, β1–3 or γ2 GABA
A
R subunits in the superior temporal gyrus (STG) in schizophrenia, the α1, β1 and β2 GABA
A
R subunits are abnormally
N
-glycosylated.
N
-glycosylation is a posttranslational modification that has important functional roles in protein folding, multimer assembly and forward trafficking. To investigate the impact that altered
N
-glycosylation has on the assembly and trafficking of GABA
A
Rs in schizophrenia, this study used western blot analysis to measure the expression of α1, α2, β1, β2 and γ2 GABA
A
R subunits in subcellular fractions enriched for endoplasmic reticulum (ER) and synapses (SYN) from STG of schizophrenia (
N
=16) and comparison (
N
=14) subjects and found evidence of abnormal localization of the β1 and β2 GABA
A
R subunits and subunit isoforms in schizophrenia. The β2 subunit is expressed as three isoforms at 52 kDa (β2
52 kDa
), 50 kDa (β2
50 kDa
) and 48 kDa (β2
48 kDa
). In the ER, we found increased total β2 GABA
A
R subunit (β2
ALL
) expression driven by increased β2
50 kDa
, a decreased ratio of β2
48 kDa
:β2
ALL
and an increased ratio of β2
50 kDa
:β2
48 kDa
. Decreased ratios of β1:β2
ALL
and β1:β2
50 kDa
in both the ER and SYN fractions and an increased ratio of β2
52 kDa
:β2
48 kDa
at the synapse were also identified in schizophrenia. Taken together, these findings provide evidence that alterations of
N
-glycosylation may contribute to GABAergic signaling deficits in schizophrenia by disrupting the assembly and trafficking of GABA
A
Rs. |
---|---|
AbstractList | Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA(A)R). In schizophrenia, presynaptic GABAergic signaling deficits are among the most replicated findings; however, postsynaptic GABAergic deficits are less well characterized. Our lab has previously demonstrated that although there is no difference in total protein expression of the α1-6, β1-3 or γ2 GABA(A)R subunits in the superior temporal gyrus (STG) in schizophrenia, the α1, β1 and β2 GABA(A)R subunits are abnormally N-glycosylated. N-glycosylation is a posttranslational modification that has important functional roles in protein folding, multimer assembly and forward trafficking. To investigate the impact that altered N-glycosylation has on the assembly and trafficking of GABA(A)Rs in schizophrenia, this study used western blot analysis to measure the expression of α1, α2, β1, β2 and γ2 GABA(A)R subunits in subcellular fractions enriched for endoplasmic reticulum (ER) and synapses (SYN) from STG of schizophrenia (N = 16) and comparison (N = 14) subjects and found evidence of abnormal localization of the β1 and β2 GABA(A)R subunits and subunit isoforms in schizophrenia. The β2 subunit is expressed as three isoforms at 52 kDa (β2(52 kDa)), 50 kDa (β2(50 kDa)) and 48 kDa (β2(48 kDa)). In the ER, we found increased total β2 GABA(A)R subunit (β2(ALL)) expression driven by increased β2(50 kDa), a decreased ratio of β(248 kDa):β2(ALL) and an increased ratio of β2(50 kDa):β2(48 kDa). Decreased ratios of β1:β2(ALL) and β1:β2(50 kDa) in both the ER and SYN fractions and an increased ratio of β2(52 kDa):β(248 kDa) at the synapse were also identified in schizophrenia. Taken together, these findings provide evidence that alterations of N-glycosylation may contribute to GABAergic signaling deficits in schizophrenia by disrupting the assembly and trafficking of GABA(A)Rs.Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA(A)R). In schizophrenia, presynaptic GABAergic signaling deficits are among the most replicated findings; however, postsynaptic GABAergic deficits are less well characterized. Our lab has previously demonstrated that although there is no difference in total protein expression of the α1-6, β1-3 or γ2 GABA(A)R subunits in the superior temporal gyrus (STG) in schizophrenia, the α1, β1 and β2 GABA(A)R subunits are abnormally N-glycosylated. N-glycosylation is a posttranslational modification that has important functional roles in protein folding, multimer assembly and forward trafficking. To investigate the impact that altered N-glycosylation has on the assembly and trafficking of GABA(A)Rs in schizophrenia, this study used western blot analysis to measure the expression of α1, α2, β1, β2 and γ2 GABA(A)R subunits in subcellular fractions enriched for endoplasmic reticulum (ER) and synapses (SYN) from STG of schizophrenia (N = 16) and comparison (N = 14) subjects and found evidence of abnormal localization of the β1 and β2 GABA(A)R subunits and subunit isoforms in schizophrenia. The β2 subunit is expressed as three isoforms at 52 kDa (β2(52 kDa)), 50 kDa (β2(50 kDa)) and 48 kDa (β2(48 kDa)). In the ER, we found increased total β2 GABA(A)R subunit (β2(ALL)) expression driven by increased β2(50 kDa), a decreased ratio of β(248 kDa):β2(ALL) and an increased ratio of β2(50 kDa):β2(48 kDa). Decreased ratios of β1:β2(ALL) and β1:β2(50 kDa) in both the ER and SYN fractions and an increased ratio of β2(52 kDa):β(248 kDa) at the synapse were also identified in schizophrenia. Taken together, these findings provide evidence that alterations of N-glycosylation may contribute to GABAergic signaling deficits in schizophrenia by disrupting the assembly and trafficking of GABA(A)Rs. Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA(A)R). In schizophrenia, presynaptic GABAergic signaling deficits are among the most replicated findings; however, postsynaptic GABAergic deficits are less well characterized. Our lab has previously demonstrated that although there is no difference in total protein expression of the α1-6, β1-3 or γ2 GABA(A)R subunits in the superior temporal gyrus (STG) in schizophrenia, the α1, β1 and β2 GABA(A)R subunits are abnormally N-glycosylated. N-glycosylation is a posttranslational modification that has important functional roles in protein folding, multimer assembly and forward trafficking. To investigate the impact that altered N-glycosylation has on the assembly and trafficking of GABA(A)Rs in schizophrenia, this study used western blot analysis to measure the expression of α1, α2, β1, β2 and γ2 GABA(A)R subunits in subcellular fractions enriched for endoplasmic reticulum (ER) and synapses (SYN) from STG of schizophrenia (N = 16) and comparison (N = 14) subjects and found evidence of abnormal localization of the β1 and β2 GABA(A)R subunits and subunit isoforms in schizophrenia. The β2 subunit is expressed as three isoforms at 52 kDa (β2(52 kDa)), 50 kDa (β2(50 kDa)) and 48 kDa (β2(48 kDa)). In the ER, we found increased total β2 GABA(A)R subunit (β2(ALL)) expression driven by increased β2(50 kDa), a decreased ratio of β(248 kDa):β2(ALL) and an increased ratio of β2(50 kDa):β2(48 kDa). Decreased ratios of β1:β2(ALL) and β1:β2(50 kDa) in both the ER and SYN fractions and an increased ratio of β2(52 kDa):β(248 kDa) at the synapse were also identified in schizophrenia. Taken together, these findings provide evidence that alterations of N-glycosylation may contribute to GABAergic signaling deficits in schizophrenia by disrupting the assembly and trafficking of GABA(A)Rs. Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA A R). In schizophrenia, presynaptic GABAergic signaling deficits are among the most replicated findings; however, postsynaptic GABAergic deficits are less well characterized. Our lab has previously demonstrated that although there is no difference in total protein expression of the α1–6, β1–3 or γ2 GABA A R subunits in the superior temporal gyrus (STG) in schizophrenia, the α1, β1 and β2 GABA A R subunits are abnormally N -glycosylated. N -glycosylation is a posttranslational modification that has important functional roles in protein folding, multimer assembly and forward trafficking. To investigate the impact that altered N -glycosylation has on the assembly and trafficking of GABA A Rs in schizophrenia, this study used western blot analysis to measure the expression of α1, α2, β1, β2 and γ2 GABA A R subunits in subcellular fractions enriched for endoplasmic reticulum (ER) and synapses (SYN) from STG of schizophrenia ( N =16) and comparison ( N =14) subjects and found evidence of abnormal localization of the β1 and β2 GABA A R subunits and subunit isoforms in schizophrenia. The β2 subunit is expressed as three isoforms at 52 kDa (β2 52 kDa ), 50 kDa (β2 50 kDa ) and 48 kDa (β2 48 kDa ). In the ER, we found increased total β2 GABA A R subunit (β2 ALL ) expression driven by increased β2 50 kDa , a decreased ratio of β2 48 kDa :β2 ALL and an increased ratio of β2 50 kDa :β2 48 kDa . Decreased ratios of β1:β2 ALL and β1:β2 50 kDa in both the ER and SYN fractions and an increased ratio of β2 52 kDa :β2 48 kDa at the synapse were also identified in schizophrenia. Taken together, these findings provide evidence that alterations of N -glycosylation may contribute to GABAergic signaling deficits in schizophrenia by disrupting the assembly and trafficking of GABA A Rs. Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABAA R). In schizophrenia, presynaptic GABAergic signaling deficits are among the most replicated findings; however, postsynaptic GABAergic deficits are less well characterized. Our lab has previously demonstrated that although there is no difference in total protein expression of the α1-6, β1-3 or γ2 GABA A R subunits in the superior temporal gyrus (STG) in schizophrenia, the α1, β1 and β2 GABAA R subunits are abnormally N-glycosylated. N-glycosylation is a posttranslational modification that has important functional roles in protein folding, multimer assembly and forward trafficking. To investigate the impact that altered N-glycosylation has on the assembly and trafficking of GABA A Rs in schizophrenia, this study used western blot analysis to measure the expression of α1, α2, β1, β2 and γ2 GABAA R subunits in subcellular fractions enriched for endoplasmic reticulum (ER) and synapses (SYN) from STG of schizophrenia (N=16) and comparison (N=14) subjects and found evidence of abnormal localization of the β1 and β2 GABAA R subunits and subunit isoforms in schizophrenia. The β2 subunit is expressed as three isoforms at 52 kDa (β252 kDa ), 50 kDa (β250 kDa ) and 48 kDa (β248 kDa ). In the ER, we found increased total β2 GABAA R subunit (β2ALL ) expression driven by increased β250 kDa , a decreased ratio of β248 kDa :β2ALL and an increased ratio of β250 kDa :β248 kDa . Decreased ratios of β1:β2ALL and β1:β250 kDa in both the ER and SYN fractions and an increased ratio of β252 kDa :β248 kDa at the synapse were also identified in schizophrenia. Taken together, these findings provide evidence that alterations of N-glycosylation may contribute to GABAergic signaling deficits in schizophrenia by disrupting the assembly and trafficking of GABAA Rs. Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA A R). In schizophrenia, presynaptic GABAergic signaling deficits are among the most replicated findings; however, postsynaptic GABAergic deficits are less well characterized. Our lab has previously demonstrated that although there is no difference in total protein expression of the α1–6, β1–3 or γ2 GABA A R subunits in the superior temporal gyrus (STG) in schizophrenia, the α1, β1 and β2 GABA A R subunits are abnormally N -glycosylated. N -glycosylation is a posttranslational modification that has important functional roles in protein folding, multimer assembly and forward trafficking. To investigate the impact that altered N -glycosylation has on the assembly and trafficking of GABA A Rs in schizophrenia, this study used western blot analysis to measure the expression of α1, α2, β1, β2 and γ2 GABA A R subunits in subcellular fractions enriched for endoplasmic reticulum (ER) and synapses (SYN) from STG of schizophrenia ( N =16) and comparison ( N =14) subjects and found evidence of abnormal localization of the β1 and β2 GABA A R subunits and subunit isoforms in schizophrenia. The β2 subunit is expressed as three isoforms at 52 kDa (β2 52 kDa ), 50 kDa (β2 50 kDa ) and 48 kDa (β2 48 kDa ). In the ER, we found increased total β2 GABA A R subunit (β2 ALL ) expression driven by increased β2 50 kDa , a decreased ratio of β2 48 kDa :β2 ALL and an increased ratio of β2 50 kDa :β2 48 kDa . Decreased ratios of β1:β2 ALL and β1:β2 50 kDa in both the ER and SYN fractions and an increased ratio of β2 52 kDa :β2 48 kDa at the synapse were also identified in schizophrenia. Taken together, these findings provide evidence that alterations of N -glycosylation may contribute to GABAergic signaling deficits in schizophrenia by disrupting the assembly and trafficking of GABA A Rs. |
Author | Haroutunian, V Remedies, C E Mueller, T M Meador-Woodruff, J H |
Author_xml | – sequence: 1 givenname: T M surname: Mueller fullname: Mueller, T M email: toni314@uab.edu organization: Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham – sequence: 2 givenname: C E surname: Remedies fullname: Remedies, C E organization: Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Science and Technology Honors Program, University of Alabama at Birmingham – sequence: 3 givenname: V surname: Haroutunian fullname: Haroutunian, V organization: Department of Psychiatry, Mount Sinai School of Medicine – sequence: 4 givenname: J H surname: Meador-Woodruff fullname: Meador-Woodruff, J H organization: Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26241350$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1LJDEQxYO4-DF68i4NXhZ0NJV0JpmL0Iq6C8Ie1HNIp9NOJJO0Sbew89ebcVRmxc0lKfKrx6t6u2jTB28QOgB8CpiKs747JRhYLsgG2iHAxJiCEJtr7220n9ITzoeVAjhsoW0yISVQhnfQXVX7EOfKFWmotXFucCoWLmjl7EL1NvgitMVNdVFVRTTadH2IS3Twtk-F9UXSM7sI3Swab1VRR2X9HvrRKpfM_vs9Qg_XV_eXv8a3f25-X1a3Y00ZJ2M11bppp4aohjXaEKNKKshkkj2KktKWU0Vxq1qMgbS0EZybkgBvKBgOBGo6Qucr3W6o5yZL-D4qJ7to5yr-lUFZ-e-PtzP5GF5kySYlYzwL_HwXiOF5MKmXc5uWS1DehCFJ4JhgwckbevQFfQpD9Hm8TE0BKEDOY4QO1x19WvnYdwaOV4COIaVo2k8EsFwGKvtOLgPNBck0fKG17d9CyeNY95-ek1VPysr-0cQ1o9_gr-aGsVk |
CitedBy_id | crossref_primary_10_1038_s41386_023_01728_8 crossref_primary_10_1126_sciadv_aau8237 crossref_primary_10_1038_s41398_017_0045_y crossref_primary_10_1038_s41586_022_04517_3 crossref_primary_10_1038_s41380_020_0761_1 crossref_primary_10_1038_s41398_023_02336_2 crossref_primary_10_1186_s12864_017_3798_z crossref_primary_10_1016_j_jpsychires_2016_12_019 crossref_primary_10_1016_j_schres_2016_10_024 crossref_primary_10_1038_s41398_019_0610_7 crossref_primary_10_1186_s43141_021_00224_0 crossref_primary_10_3390_genes15040452 crossref_primary_10_3389_fphar_2024_1457811 crossref_primary_10_1016_j_schres_2015_06_002 crossref_primary_10_1038_s41537_020_0093_9 crossref_primary_10_3389_fncel_2018_00273 crossref_primary_10_1007_s12035_024_04477_x crossref_primary_10_1002_syn_22069 crossref_primary_10_1038_npp_2015_219 crossref_primary_10_1080_15622975_2020_1731925 crossref_primary_10_1016_j_schres_2020_01_025 crossref_primary_10_1093_cercor_bhae044 crossref_primary_10_1016_j_cortex_2016_09_019 crossref_primary_10_1016_j_schres_2018_02_010 crossref_primary_10_1007_s10719_022_10055_x crossref_primary_10_1007_s00213_017_4705_7 crossref_primary_10_1016_j_bbrc_2017_08_114 crossref_primary_10_1097_WNR_0000000000000880 crossref_primary_10_1016_j_bcp_2016_03_014 crossref_primary_10_1242_jcs_247700 crossref_primary_10_1038_s41398_018_0359_4 crossref_primary_10_3389_fphar_2024_1272534 |
Cites_doi | 10.1038/nrn2370 10.1176/ajp.150.11.1726 10.1016/j.schres.2011.11.029 10.1523/JNEUROSCI.23-15-06315.2003 10.1523/JNEUROSCI.1234-11.2011 10.1038/npp.2013.190 10.3389/fncel.2012.00023 10.1038/336164a0 10.1093/schbul/sbn070 10.1073/pnas.87.24.9966 10.1523/JNEUROSCI.4011-04.2005 10.1016/S0893-133X(01)00225-1 10.1038/sj.mp.4001739 10.1016/j.biopsych.2007.05.027 10.1007/s00702-008-0143-3 10.2183/pjab.88.31 10.1001/archpsyc.57.11.1061 10.1176/appi.ajp.2008.07121845 10.1016/j.neuroscience.2008.11.006 10.1038/mp.2010.47 10.1016/S0165-0173(99)00041-7 10.1152/physrev.00015.2010 10.1016/S0022-3956(99)00039-4 10.1093/oxfordjournals.schbul.a033430 10.1146/annurev.biochem.73.011303.073752 10.1093/cercor/12.10.1063 10.1016/S0166-2236(96)80023-3 10.1074/jbc.271.1.89 10.1371/journal.pone.0009547 10.1016/j.schres.2014.01.028 10.1371/journal.pone.0006977 10.1176/appi.ajp.2007.07081223 10.1016/j.brainres.2006.09.025 10.1042/BST0371415 10.1113/jphysiol.2011.224659 10.1146/annurev.biochem.69.1.69 10.1016/j.neuropharm.2008.07.045 10.1093/glycob/12.4.43R 10.1016/S0006-3223(99)00061-X 10.1093/cercor/bhq169 10.1002/ajmg.b.32116 10.1001/archpsyc.1995.03950160008002 10.1073/pnas.0703806104 10.1093/schbul/15.3.365 10.1038/tp.2013.64 10.1016/j.schres.2009.07.025 10.1111/j.1600-0854.2009.00981.x 10.1124/pr.109.002063 10.1523/JNEUROSCI.2267-05.2005 10.1155/2011/723184 10.1016/j.schres.2005.03.020 10.1111/jnc.12083 10.1007/s00221-005-0290-9 10.1038/2798 10.1016/j.neuropharm.2009.07.027 10.1016/0169-328X(94)00228-7 10.1074/jbc.M112.444372 10.1523/JNEUROSCI.17-17-06587.1997 10.1038/sj.mp.4002011 10.1016/j.jpsychires.2009.12.007 10.1016/j.febslet.2007.04.070 10.1016/S0306-4522(99)00189-X 10.1016/j.neuron.2006.09.020 10.1016/j.schres.2013.01.031 10.1001/archpsyc.55.3.205 10.1097/WNR.0b013e328363bd8a 10.1111/j.1742-4658.2005.04595.x 10.1074/jbc.M110.151449 10.1371/journal.pone.0039190 10.1002/pmic.201000374 10.1074/jbc.M112.360461 10.1038/nrn1648 10.1111/j.1471-4159.2006.04206.x 10.1176/ajp.153.3.321 10.2174/1568026023393507 10.1007/978-0-387-30410-6_11 10.1176/appi.ajp.2008.08030395 10.1093/schbul/sbu111 10.1016/j.tins.2011.10.004 10.1038/npp.2013.84 10.1093/database/bar009 10.1001/archpsyc.57.3.237 10.1523/JNEUROSCI.22-07-02513.2002 10.1385/MN:26:2-3:251 10.1038/sj.mp.4001899 10.1016/S0896-6273(00)00085-4 10.1371/journal.pone.0036351 10.1038/npp.2011.102 10.1016/j.neuropharm.2011.01.022 10.1371/journal.pone.0034586 10.1007/s10059-010-0159-z 10.1016/j.biopsych.2010.09.052 10.1016/S0026-895X(25)13351-8 10.1111/j.2517-6161.1995.tb02031.x 10.1016/S0031-6997(25)06840-1 |
ContentType | Journal Article |
Copyright | The Author(s) 2015 Copyright Nature Publishing Group Aug 2015 Copyright © 2015 Macmillan Publishers Limited 2015 Macmillan Publishers Limited |
Copyright_xml | – notice: The Author(s) 2015 – notice: Copyright Nature Publishing Group Aug 2015 – notice: Copyright © 2015 Macmillan Publishers Limited 2015 Macmillan Publishers Limited |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1038/tp.2015.102 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Proquest Health and Medical Complete ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | GABAAR subunit localization in schizophrenia |
EISSN | 2158-3188 |
EndPage | e612 |
ExternalDocumentID | PMC4564557 4067078261 26241350 10_1038_tp_2015_102 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIMH NIH HHS grantid: MH066392 – fundername: NIMH NIH HHS grantid: R01 MH053327 – fundername: NIMH NIH HHS grantid: R01 MH064673 – fundername: NIMH NIH HHS grantid: P50 MH066392 – fundername: NIMH NIH HHS grantid: MH064673 – fundername: NIMH NIH HHS grantid: MH53327 |
GroupedDBID | --- 0R~ 3V. 4.4 53G 5VS 7X7 88E 8FI 8FJ AAJSJ AAKDD ABUWG ACGFO ACGFS ACMJI ACSMW ADBBV ADFRT AENEX AFKRA AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EJD EMOBN FYUFA GROUPED_DOAJ GX1 HMCUK HYE KQ8 LGEZI LOTEE M1P M~E NADUK NAO NXXTH OK1 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT UKHRP AASML AAYXX CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM PJZUB PPXIY 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c3572-a9ccdf9e2ad5dce2ea4382668178433f73a30faf0012f3d877e4217d31e7121b3 |
IEDL.DBID | 7X7 |
ISSN | 2158-3188 |
IngestDate | Thu Aug 21 18:23:02 EDT 2025 Mon Jul 21 11:43:51 EDT 2025 Sat Aug 23 13:52:20 EDT 2025 Mon Jul 21 05:38:30 EDT 2025 Thu Jul 03 08:39:08 EDT 2025 Thu Apr 24 23:01:22 EDT 2025 Fri Feb 21 02:38:55 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
License | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3572-a9ccdf9e2ad5dce2ea4382668178433f73a30faf0012f3d877e4217d31e7121b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/1791131110?pq-origsite=%requestingapplication% |
PMID | 26241350 |
PQID | 1791131110 |
PQPubID | 2041978 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4564557 proquest_miscellaneous_1702087257 proquest_journals_1791131110 pubmed_primary_26241350 crossref_primary_10_1038_tp_2015_102 crossref_citationtrail_10_1038_tp_2015_102 springer_journals_10_1038_tp_2015_102 |
PublicationCentury | 2000 |
PublicationDate | 2015-Aug-04 |
PublicationDateYYYYMMDD | 2015-08-04 |
PublicationDate_xml | – month: 08 year: 2015 text: 2015-Aug-04 day: 04 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: United States |
PublicationTitle | Translational psychiatry |
PublicationTitleAbbrev | Transl Psychiatry |
PublicationTitleAlternate | Transl Psychiatry |
PublicationYear | 2015 |
Publisher | Nature Publishing Group UK Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
References | Benes (CR10) 2000; 31 Green, Kern, Braff, Mintz (CR11) 2000; 26 Hyde, Lipska, Ali, Mathew, Law, Metitiri (CR18) 2011; 31 Helenius, Aebi (CR41) 2004; 73 Chen, Tsang, Zhao, Pun, Yu, Mei (CR81) 2009; 37 Zhao, Xu, Wang, Chen, Ng, Wong (CR75) 2009; 4 Olsen, Sieghart (CR87) 2009; 56 Green (CR12) 1996; 153 Spiro (CR44) 2002; 12 Connolly, Krishek, McDonald, Smart, Moss (CR57) 1996; 271 Lewis, Pierri, Volk, Melchitzky, Woo (CR7) 1999; 46 Cai, Salonikidis, Fei, Schwarz, Schülein, Reutter (CR42) 2005; 272 Pato, Lander, Schulz (CR79) 1989; 15 Beneyto, Abbott, Hashimoto, Lewis (CR28) 2011; 21 Lewis, Cho, Carter (CR59) 2008; 165 Stan, Ghose, Gao, Roberts, Lewis-Amezcua, Hatanpaa (CR69) 2006; 1123 Honea, Meyer-Lindenberg, Hobbs, Pezawas, Mattay, Egan (CR39) 2008; 63 Whiting, McKernan, Iversen (CR27) 1990; 87 Zhao, Xu, Chen, Yu, Tong, Lo (CR82) 2006; 11 Volk, Austin, Pierri, Sampson, Lewis (CR20) 2000; 57 Vithlani, Terunuma, Moss (CR54) 2011; 91 Shan, Mount, Moore, Haroutunian, Meador-Woodruff, McCullumsmith (CR67) 2014; 154 Kang, Heo, Lubec (CR90) 2011; 11 Duncan, Webster, Rothmond, Bahn, Elashoff, Weickert (CR31) 2010; 44 Chen, Xu, Zhang, Liu, Xu, Shen (CR38) 2013; 162B Sieghart (CR25) 1995; 47 Volk (CR60) 2002; 12 Smiley (CR40) 2009 Benes, Lim, Matzilevich, Walsh, Subburaju, Minns (CR19) 2007; 104 Volk, Lewis (CR8) 2014; 40 Ito, Takeda (CR47) 2012; 88 Alldred, Mulder-Rosi, Lingenfelter, Chen, Lüscher (CR58) 2005; 25 Chen, Olsen (CR95) 2007; 100 Wu, Wang, Beveridge, Tooney, Scott, Carr (CR33) 2012; 7 Bayer, Falkai, Maier (CR84) 1999; 33 Guidotti, Auta, Davis, Gerevini, Dwivedi, Grayson (CR14) 2000; 57 Charych, Liu, Moss, Brandon (CR6) 2009; 57 Hammond, Meador-Woodruff, Haroutunian, McCullumsmith (CR66) 2012; 7 Ohnuma, Augood, Arai, McKenna, Emson (CR30) 1999; 93 Powchik, Davidson, Nemeroff, Haroutunian, Purohit, Losonczy (CR63) 1993; 150 Hashimoto, Volk, Eggan, Mirnics, Pierri, Sun (CR16) 2003; 23 Deng, Huang (CR37) 2006; 168 Jacob, Moss, Jurd (CR53) 2008; 9 Ng, Lo, Pun, Zhao, Yu, Chen (CR80) 2010; 5 Klausberger, Roberts, Somogyi (CR88) 2002; 22 Zhao, Wang, Pun, Mei, Ren, Yu (CR74) 2012; 134 Hashimoto, Arion, Unger, Maldonado-Avilés, Morris, Volk (CR15) 2008; 13 Tretter, Mukherjee, Maric, Schindelin, Sieghart, Moss (CR71) 2012; 6 Tucholski, Simmons, Pinner, McMillan, Haroutunian, Meador-Woodruff (CR50) 2013; 24 Benes, Berretta (CR23) 2001; 25 Uhlhaas, Singer (CR4) 2006; 52 Nakazawa, Zsiros, Jiang, Nakao, Kolata, Zhang (CR5) 2012; 62 Bauer, Haroutunian, McCullumsmith, Meador-Woodruff (CR70) 2009; 116 Magrane (CR77) 2011; 2011 Akbarian, Kim, Potkin, Hagman, Tafazzoli, Bunney (CR13) 1995; 52 Hadingham, Wingrove, Wafford, Bain, Kemp, Palmer (CR89) 1993; 44 Jacob, Bogdanov, Magnus, Saliba, Kittler, Haydon (CR72) 2005; 25 Curley, Lewis (CR9) 2012; 590 Mueller, Haroutunian, Meador-Woodruff (CR36) 2014; 39 Tucholski, Simmons, Pinner, Haroutunian, McCullumsmith, Meador-Woodruff (CR49) 2013; 146 Benjamini, Hochberg (CR73) 1995; 57 Zhou, Huang, Ding, Deel, Arain, Murray (CR85) 2013; 288 Mirnics, Middleton, Marquez, Lewis, Levitt (CR21) 2000; 28 McKinley, Lennon, Carter (CR76) 1995; 28 Petryshen, Middleton, Tahl, Rockwell, Purcell, Aldinger (CR34) 2005; 10 Olivari, Molinari (CR48) 2007; 581 Laha, Tran (CR91) 2013; 124 Lewis, Curley, Glausier, Volk (CR3) 2012; 35 Wu, Wu, Ning, Guo, Ali, MacDonald (CR86) 2012; 287 Sherrington, Brynjolfsson, Petursson, Potter, Dudleston, Barraclough (CR78) 1988; 336 Bauer, Haroutunian, Meador-Woodruff, McCullumsmith (CR51) 2010; 117 McKernan, Whiting (CR26) 1996; 19 Roth, Zuber, Park, Jang, Lee, Kysela (CR45) 2010; 30 Hashimoto, Bazmi, Mirnics, Wu, Sampson, Lewis (CR17) 2008; 165 Lewis, Hashimoto, Volk (CR2) 2005; 6 Lo, Lagrange, Hernandez, Harrison, Dell, Haslam (CR93) 2010; 285 Pun, Zhao, Lo, Ng, Tsang, Nimgaonkar (CR83) 2011; 16 Buchanan, Keefe, Lieberman, Barch, Csernansky, Goff (CR61) 2011; 69 Purohit, Perl, Haroutunian, Powchik, Davidson, Davis (CR65) 1998; 55 Essrich, Lorez, Benson, Fritschy, Lüscher (CR56) 1998; 1 Bullock, Cardon, Bustillo, Roberts, Perrone-Bizzozero (CR35) 2008; 165 Gonzalez-Burgos, Lewis (CR22) 2008; 34 Gonzalez-Burgos, Fish, Lewis (CR1) 2011; 2011 Uusi-Oukari, Korpi (CR92) 2010; 62 Glausier, Lewis (CR29) 2011; 36 Fatemi, Folsom, Rooney, Thuras (CR32) 2013; 3 Kittler, McAinsh, Moss (CR55) 2002; 26 Mulligan, Wang, Adler, Mozhui, Lu, Williams (CR24) 2012; 7 Dennis, Lau, Demetriou, Nabi (CR43) 2009; 10 Katsel, Davis, Gorman, Haroutunian (CR64) 2005; 77 Sieghart, Sperk (CR52) 2002; 2 Goebel-Goody, Davies, Alvestad Linger, Freund, Browning (CR68) 2009; 158 Rubio, Wood, Haroutunian, Meador-Woodruff (CR62) 2013; 38 Parodi (CR46) 2000; 69 Gorrie, Vallis, Stephenson, Whitfield, Browning, Smart (CR94) 1997; 17 DA Lewis (BFtp2015102_CR3) 2012; 35 C Zhao (BFtp2015102_CR74) 2012; 134 WM Bullock (BFtp2015102_CR35) 2008; 165 AJ Parodi (BFtp2015102_CR46) 2000; 69 MF Green (BFtp2015102_CR12) 1996; 153 FM Benes (BFtp2015102_CR23) 2001; 25 P Powchik (BFtp2015102_CR63) 1993; 150 TC Jacob (BFtp2015102_CR72) 2005; 25 SM Goebel-Goody (BFtp2015102_CR68) 2009; 158 J Roth (BFtp2015102_CR45) 2010; 30 KL Hadingham (BFtp2015102_CR89) 1993; 44 R Sherrington (BFtp2015102_CR78) 1988; 336 C Zhou (BFtp2015102_CR85) 2013; 288 T Klausberger (BFtp2015102_CR88) 2002; 22 M Beneyto (BFtp2015102_CR28) 2011; 21 D Shan (BFtp2015102_CR67) 2014; 154 TM Hyde (BFtp2015102_CR18) 2011; 31 M Vithlani (BFtp2015102_CR54) 2011; 91 M Magrane (BFtp2015102_CR77) 2011; 2011 C Zhao (BFtp2015102_CR82) 2006; 11 T Hashimoto (BFtp2015102_CR16) 2003; 23 C Deng (BFtp2015102_CR37) 2006; 168 DE Bauer (BFtp2015102_CR51) 2010; 117 JC Hammond (BFtp2015102_CR66) 2012; 7 FM Benes (BFtp2015102_CR19) 2007; 104 S Akbarian (BFtp2015102_CR13) 1995; 52 J Tucholski (BFtp2015102_CR49) 2013; 146 P Katsel (BFtp2015102_CR64) 2005; 77 G Cai (BFtp2015102_CR42) 2005; 272 JQ Wu (BFtp2015102_CR33) 2012; 7 DA Lewis (BFtp2015102_CR59) 2008; 165 PJ Uhlhaas (BFtp2015102_CR4) 2006; 52 P Whiting (BFtp2015102_CR27) 1990; 87 Y Benjamini (BFtp2015102_CR73) 1995; 57 K Nakazawa (BFtp2015102_CR5) 2012; 62 W Sieghart (BFtp2015102_CR52) 2002; 2 DW Volk (BFtp2015102_CR8) 2014; 40 T Ohnuma (BFtp2015102_CR30) 1999; 93 J Tucholski (BFtp2015102_CR50) 2013; 24 DW Volk (BFtp2015102_CR20) 2000; 57 DP Purohit (BFtp2015102_CR65) 1998; 55 TC Jacob (BFtp2015102_CR53) 2008; 9 GH Gorrie (BFtp2015102_CR94) 1997; 17 JR Glausier (BFtp2015102_CR29) 2011; 36 Y Ito (BFtp2015102_CR47) 2012; 88 D McKinley (BFtp2015102_CR76) 1995; 28 DA Lewis (BFtp2015102_CR2) 2005; 6 TA Bayer (BFtp2015102_CR84) 1999; 33 DA Lewis (BFtp2015102_CR7) 1999; 46 DE Bauer (BFtp2015102_CR70) 2009; 116 CE Duncan (BFtp2015102_CR31) 2010; 44 C Essrich (BFtp2015102_CR56) 1998; 1 V Tretter (BFtp2015102_CR71) 2012; 6 MF Green (BFtp2015102_CR11) 2000; 26 J Chen (BFtp2015102_CR38) 2013; 162B RW Buchanan (BFtp2015102_CR61) 2011; 69 X Wu (BFtp2015102_CR86) 2012; 287 CN Connolly (BFtp2015102_CR57) 1996; 271 C Zhao (BFtp2015102_CR75) 2009; 4 K Mirnics (BFtp2015102_CR21) 2000; 28 S Olivari (BFtp2015102_CR48) 2007; 581 J Chen (BFtp2015102_CR81) 2009; 37 AR Guidotti (BFtp2015102_CR14) 2000; 57 JT Kittler (BFtp2015102_CR55) 2002; 26 CN Pato (BFtp2015102_CR79) 1989; 15 FW Pun (BFtp2015102_CR83) 2011; 16 RG Spiro (BFtp2015102_CR44) 2002; 12 DW Volk (BFtp2015102_CR60) 2002; 12 T Hashimoto (BFtp2015102_CR15) 2008; 13 RM McKernan (BFtp2015102_CR26) 1996; 19 JF Smiley (BFtp2015102_CR40) 2009 M Uusi-Oukari (BFtp2015102_CR92) 2010; 62 A Helenius (BFtp2015102_CR41) 2004; 73 MD Rubio (BFtp2015102_CR62) 2013; 38 MJ Alldred (BFtp2015102_CR58) 2005; 25 W Sieghart (BFtp2015102_CR25) 1995; 47 TL Petryshen (BFtp2015102_CR34) 2005; 10 RA Honea (BFtp2015102_CR39) 2008; 63 WY Lo (BFtp2015102_CR93) 2010; 285 AA Curley (BFtp2015102_CR9) 2012; 590 FM Benes (BFtp2015102_CR10) 2000; 31 JW Dennis (BFtp2015102_CR43) 2009; 10 G Gonzalez-Burgos (BFtp2015102_CR22) 2008; 34 AD Stan (BFtp2015102_CR69) 2006; 1123 RW Olsen (BFtp2015102_CR87) 2009; 56 KT Laha (BFtp2015102_CR91) 2013; 124 SH Fatemi (BFtp2015102_CR32) 2013; 3 Z-W Chen (BFtp2015102_CR95) 2007; 100 EI Charych (BFtp2015102_CR6) 2009; 57 T Hashimoto (BFtp2015102_CR17) 2008; 165 MK Mulligan (BFtp2015102_CR24) 2012; 7 SU Kang (BFtp2015102_CR90) 2011; 11 G Gonzalez-Burgos (BFtp2015102_CR1) 2011; 2011 S-K Ng (BFtp2015102_CR80) 2010; 5 TM Mueller (BFtp2015102_CR36) 2014; 39 10465426 - Neuroscience. 1999;93(2):441-8 15659595 - J Neurosci. 2005 Jan 19;25(3):594-603 20404824 - Mol Psychiatry. 2011 May;16(5):557-68 21277876 - Neuropharmacology. 2012 Mar;62(3):1574-83 8214183 - Am J Psychiatry. 1993 Nov;150(11):1726-7 8610818 - Am J Psychiatry. 1996 Mar;153(3):321-30 23917429 - Neuropsychopharmacology. 2014 Feb;39(3):528-37 8658597 - Trends Neurosci. 1996 Apr;19(4):139-43 18760291 - Neuropharmacology. 2009 Jan;56(1):141-8 21447597 - Database (Oxford). 2011;2011:bar009 10472415 - Biol Psychiatry. 1999 Sep 1;46(5):616-26 23744069 - J Biol Chem. 2013 Jul 19;288(29):21458-72 18281411 - Am J Psychiatry. 2008 Apr;165(4):479-89 15923110 - Schizophr Res. 2005 Sep 15;77(2-3):241-52 17553960 - Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10164-9 10711910 - Arch Gen Psychiatry. 2000 Mar;57(3):237-45 20100621 - J Psychiatr Res. 2010 Jul;44(10):673-81 12042244 - Glycobiology. 2002 Apr;12(4):43R-56R 16362364 - Exp Brain Res. 2006 Jan;168(4):587-90 19763268 - PLoS One. 2009;4(9):e6977 24022508 - Transl Psychiatry. 2013;3:e303 10719152 - Brain Res Brain Res Rev. 2000 Mar;31(2-3):251-69 17499246 - FEBS Lett. 2007 Jul 31;581(19):3658-64 1702226 - Proc Natl Acad Sci U S A. 1990 Dec;87(24):9966-70 18923069 - Am J Psychiatry. 2008 Dec;165(12):1594-603 18923067 - Am J Psychiatry. 2008 Dec;165(12):1585-93 21538884 - Proteomics. 2011 Jun;11(11):2171-81 8264558 - Mol Pharmacol. 1993 Dec;44(6):1211-8 10755673 - Schizophr Bull. 2000;26(1):119-36 2683037 - Schizophr Bull. 1989;15(3):365-72 23462048 - Schizophr Res. 2013 May;146(1-3):177-83 19139805 - J Neural Transm (Vienna). 2009 Apr;116(4):487-91 19631671 - Neuropharmacology. 2009 Oct-Nov;57(5-6):481-95 20843900 - Cereb Cortex. 2011 May;21(5):999-1011 23169775 - Am J Med Genet B Neuropsychiatr Genet. 2013 Jan;162B(1):36-43 20123953 - Pharmacol Rev. 2010 Mar;62(1):97-135 21145041 - Biol Psychiatry. 2011 Mar 1;69(5):442-9 11377916 - Neuropsychopharmacology. 2001 Jul;25(1):1-27 18586694 - Schizophr Bull. 2008 Sep;34(5):944-61 16983389 - Mol Psychiatry. 2006 Dec;11(12):1092-105 22558445 - PLoS One. 2012;7(4):e36351 19716271 - Schizophr Res. 2010 Mar;117(1):92-8 22314014 - Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(2):31-40 10628531 - J Psychiatr Res. 1999 Nov-Dec;33(6):543-8 10196563 - Nat Neurosci. 1998 Nov;1(7):563-71 23820740 - Neuroreport. 2013 Aug 21;24(12):688-91 9254671 - J Neurosci. 1997 Sep 1;17(17):6587-96 20221451 - PLoS One. 2010;5(3):e9547 22615685 - Front Cell Neurosci. 2012 May 15;6:23 22711532 - J Biol Chem. 2012 Aug 10;287(33):27417-30 12217970 - Cereb Cortex. 2002 Oct;12(10):1063-70 7707873 - Brain Res Mol Brain Res. 1995 Jan;28(1):175-9 21677653 - Neuropsychopharmacology. 2011 Sep;36(10):2103-10 21904685 - Neural Plast. 2011;2011:723184 11086983 - Neuron. 2000 Oct;28(1):53-67 16172613 - Mol Psychiatry. 2005 Dec;10(12):1074-88, 1057 11074872 - Arch Gen Psychiatry. 2000 Nov;57(11):1061-9 7702443 - Arch Gen Psychiatry. 1995 Apr;52(4):258-66 19041929 - Neuroscience. 2009 Feb 18;158(4):1446-59 15189166 - Annu Rev Biochem. 2004;73:1019-49 15794750 - FEBS J. 2005 Apr;272(7):1625-38 22206711 - Schizophr Res. 2012 Feb;134(2-3):260-6 11923416 - J Neurosci. 2002 Apr 1;22(7):2513-21 22506031 - PLoS One. 2012;7(4):e34586 15803162 - Nat Rev Neurosci. 2005 Apr;6(4):312-24 16280585 - J Neurosci. 2005 Nov 9;25(45):10469-78 19909288 - Biochem Soc Trans. 2009 Dec;37(Pt 6):1415-8 12428759 - Mol Neurobiol. 2002 Oct-Dec;26(2-3):251-68 20639197 - J Biol Chem. 2010 Oct 8;285(41):31348-61 17689500 - Biol Psychiatry. 2008 Mar 1;63(5):465-74 12867516 - J Neurosci. 2003 Jul 16;23(15):6315-26 21795557 - J Neurosci. 2011 Jul 27;31(30):11088-95 12171572 - Curr Top Med Chem. 2002 Aug;2(8):795-816 9510214 - Arch Gen Psychiatry. 1998 Mar;55(3):205-11 23121119 - J Neurochem. 2013 Jan;124(2):200-9 25053651 - Schizophr Bull. 2014 Sep;40(5):952-7 18382465 - Nat Rev Neurosci. 2008 May;9(5):331-43 17045977 - Brain Res. 2006 Dec 6;1123(1):1-11 2903449 - Nature. 1988 Nov 10;336(6195):164-7 22154068 - Trends Neurosci. 2012 Jan;35(1):57-67 22720072 - PLoS One. 2012;7(6):e39190 17015233 - Neuron. 2006 Oct 5;52(1):155-68 17083446 - J Neurochem. 2007 Jan;100(2):279-94 22219337 - J Physiol. 2012 Feb 15;590(4):715-24 21340671 - Mol Cells. 2010 Dec;30(6):497-506 21742794 - Physiol Rev. 2011 Jul;91(3):1009-22 8550630 - J Biol Chem. 1996 Jan 5;271(1):89-96 17471287 - Mol Psychiatry. 2008 Feb;13(2):147-61 7568326 - Pharmacol Rev. 1995 Jun;47(2):181-234 23571678 - Neuropsychopharmacology. 2013 Sep;38(10):1910-20 24560881 - Schizophr Res. 2014 Apr;154(1-3):1-13 19761541 - Traffic. 2009 Nov;10(11):1569-78 10966453 - Annu Rev Biochem. 2000;69:69-93 |
References_xml | – volume: 9 start-page: 331 year: 2008 end-page: 343 ident: CR53 article-title: GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition publication-title: Nat Rev Neurosci doi: 10.1038/nrn2370 – volume: 150 start-page: 1726 year: 1993 end-page: 1727 ident: CR63 article-title: Alzheimer’s-disease-related protein in geriatric schizophrenic patients with cognitive impairment publication-title: Am J Psychiatry doi: 10.1176/ajp.150.11.1726 – volume: 134 start-page: 260 year: 2012 end-page: 266 ident: CR74 article-title: Epigenetic regulation on GABRB2 isoforms expression: developmental variations and disruptions in psychotic disorders publication-title: Schizophr Res doi: 10.1016/j.schres.2011.11.029 – volume: 23 start-page: 6315 year: 2003 end-page: 6326 ident: CR16 article-title: Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia publication-title: J Neurosci doi: 10.1523/JNEUROSCI.23-15-06315.2003 – volume: 31 start-page: 11088 year: 2011 end-page: 11095 ident: CR18 article-title: Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia publication-title: J Neurosci doi: 10.1523/JNEUROSCI.1234-11.2011 – volume: 39 start-page: 528 year: 2014 end-page: 537 ident: CR36 article-title: -Glycosylation of GABAA receptor subunits is altered in Schizophrenia publication-title: Neuropsychopharmacology doi: 10.1038/npp.2013.190 – volume: 6 start-page: 23 year: 2012 ident: CR71 article-title: Gephyrin, the enigmatic organizer at GABAergic synapses publication-title: Front Cell Neurosci doi: 10.3389/fncel.2012.00023 – volume: 336 start-page: 164 year: 1988 end-page: 167 ident: CR78 article-title: Localization of a susceptibility locus for schizophrenia on chromosome 5 publication-title: Nature doi: 10.1038/336164a0 – volume: 34 start-page: 944 year: 2008 end-page: 961 ident: CR22 article-title: GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia publication-title: Schizophr Bull doi: 10.1093/schbul/sbn070 – volume: 87 start-page: 9966 year: 1990 end-page: 9970 ident: CR27 article-title: Another mechanism for creating diversity in gamma-aminobutyrate type A receptors: RNA splicing directs expression of two forms of gamma 2 phosphorylation site publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.87.24.9966 – volume: 44 start-page: 1211 year: 1993 end-page: 1218 ident: CR89 article-title: Role of the beta subunit in determining the pharmacology of human gamma-aminobutyric acid type A receptors publication-title: Mol Pharmacol – volume: 25 start-page: 594 year: 2005 end-page: 603 ident: CR58 article-title: Distinct gamma2 subunit domains mediate clustering and synaptic function of postsynaptic GABAA receptors and gephyrin publication-title: J Neurosci doi: 10.1523/JNEUROSCI.4011-04.2005 – volume: 25 start-page: 1 year: 2001 end-page: 27 ident: CR23 article-title: GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(01)00225-1 – volume: 10 start-page: 1074 year: 2005 end-page: 1088 ident: CR34 article-title: Genetic investigation of chromosome 5q GABAA receptor subunit genes in schizophrenia publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4001739 – volume: 63 start-page: 465 year: 2008 end-page: 474 ident: CR39 article-title: Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2007.05.027 – volume: 116 start-page: 487 year: 2009 end-page: 491 ident: CR70 article-title: Expression of four housekeeping proteins in elderly patients with schizophrenia publication-title: J Neural Transm doi: 10.1007/s00702-008-0143-3 – volume: 88 start-page: 31 year: 2012 end-page: 40 ident: CR47 article-title: Analysis of glycoprotein processing in the endoplasmic reticulum using synthetic oligosaccharides publication-title: Proc Jpn Acad Ser B Phys Biol Sci doi: 10.2183/pjab.88.31 – volume: 57 start-page: 1061 year: 2000 end-page: 1069 ident: CR14 article-title: Decrease in reelin and glutamic acid decarboxylase 67 (GAD 67 ) expression in schizophrenia and bipolar disorder publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.57.11.1061 – volume: 165 start-page: 1594 year: 2008 end-page: 1603 ident: CR35 article-title: Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2008.07121845 – volume: 158 start-page: 1446 year: 2009 end-page: 1459 ident: CR68 article-title: Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices publication-title: Neuroscience doi: 10.1016/j.neuroscience.2008.11.006 – volume: 16 start-page: 557 year: 2011 end-page: 568 ident: CR83 article-title: Imprinting in the schizophrenia candidate gene GABRB2 encoding GABA(A) receptor β(2) subunit publication-title: Mol Psychiatry doi: 10.1038/mp.2010.47 – volume: 31 start-page: 251 year: 2000 end-page: 269 ident: CR10 article-title: Emerging principles of altered neural circuitry in schizophrenia publication-title: Brain Res Rev doi: 10.1016/S0165-0173(99)00041-7 – volume: 91 start-page: 1009 year: 2011 end-page: 1022 ident: CR54 article-title: The dynamic modulation of GABA(A) receptor trafficking and its role in regulating the plasticity of inhibitory synapses publication-title: Physiol Rev doi: 10.1152/physrev.00015.2010 – volume: 33 start-page: 543 year: 1999 end-page: 548 ident: CR84 article-title: Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the ‘Two hit hypothesis.’ publication-title: J Psychiatr Res doi: 10.1016/S0022-3956(99)00039-4 – volume: 26 start-page: 119 year: 2000 end-page: 136 ident: CR11 article-title: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘right stuff’? publication-title: Schizophr Bull doi: 10.1093/oxfordjournals.schbul.a033430 – volume: 73 start-page: 1019 year: 2004 end-page: 1049 ident: CR41 article-title: Roles of -linked glycans in the endoplasmic reticulum publication-title: Annu Rev Biochem. doi: 10.1146/annurev.biochem.73.011303.073752 – volume: 12 start-page: 1063 year: 2002 end-page: 1070 ident: CR60 article-title: Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia publication-title: Cereb Cortex doi: 10.1093/cercor/12.10.1063 – volume: 19 start-page: 139 year: 1996 end-page: 143 ident: CR26 article-title: Which GABAA-receptor subtypes really occur in the brain? publication-title: Trends Neurosci doi: 10.1016/S0166-2236(96)80023-3 – volume: 271 start-page: 89 year: 1996 end-page: 96 ident: CR57 article-title: Assembly and cell surface expression of heteromeric and homomeric gamma-aminobutyric acid type A receptors publication-title: J Biol Chem doi: 10.1074/jbc.271.1.89 – volume: 5 start-page: e9547 year: 2010 ident: CR80 article-title: A recombination hotspot in a schizophrenia-associated region of GABRB2 publication-title: PLoS One doi: 10.1371/journal.pone.0009547 – volume: 154 start-page: 1 year: 2014 end-page: 13 ident: CR67 article-title: Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia publication-title: Schizophr Res doi: 10.1016/j.schres.2014.01.028 – volume: 4 start-page: e6977 year: 2009 ident: CR75 article-title: Alternative-splicing in the exon-10 region of GABA(A) receptor beta(2) subunit gene: relationships between novel isoforms and psychotic disorders publication-title: PLoS One doi: 10.1371/journal.pone.0006977 – volume: 165 start-page: 479 year: 2008 end-page: 489 ident: CR17 article-title: Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2007.07081223 – volume: 1123 start-page: 1 year: 2006 end-page: 11 ident: CR69 article-title: Human postmortem tissue: what quality markers matter? publication-title: Brain Res doi: 10.1016/j.brainres.2006.09.025 – volume: 37 start-page: 1415 issue: Pt 6 year: 2009 end-page: 1418 ident: CR81 article-title: GABRB2 in schizophrenia and bipolar disorder: disease association, gene expression and clinical correlations publication-title: Biochem Soc Trans doi: 10.1042/BST0371415 – volume: 590 start-page: 715 issue: Pt 4 year: 2012 end-page: 724 ident: CR9 article-title: Cortical basket cell dysfunction in schizophrenia publication-title: J Physiol doi: 10.1113/jphysiol.2011.224659 – volume: 69 start-page: 69 year: 2000 end-page: 93 ident: CR46 article-title: Protein glucosylation and its role in protein folding publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.69.1.69 – volume: 56 start-page: 141 year: 2009 end-page: 148 ident: CR87 article-title: GABA A receptors: subtypes provide diversity of function and pharmacology publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2008.07.045 – volume: 12 start-page: 43R year: 2002 end-page: 56R ident: CR44 article-title: Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds publication-title: Glycobiology doi: 10.1093/glycob/12.4.43R – volume: 46 start-page: 616 year: 1999 end-page: 626 ident: CR7 article-title: Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(99)00061-X – volume: 21 start-page: 999 year: 2011 end-page: 1011 ident: CR28 article-title: Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia publication-title: Cereb Cortex doi: 10.1093/cercor/bhq169 – volume: 162B start-page: 36 year: 2013 end-page: 43 ident: CR38 article-title: Comparative study of regional homogeneity in schizophrenia and major depressive disorder publication-title: Am J Med Genet B Neuropsychiatr Genet doi: 10.1002/ajmg.b.32116 – volume: 52 start-page: 258 year: 1995 end-page: 266 ident: CR13 article-title: Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1995.03950160008002 – volume: 57 start-page: 289 year: 1995 end-page: 300 ident: CR73 article-title: Controlling the false discovery rate: a practical and powerful approach to multiple testing publication-title: J R Stat Soc – volume: 104 start-page: 10164 year: 2007 end-page: 10169 ident: CR19 article-title: Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0703806104 – volume: 15 start-page: 365 year: 1989 end-page: 372 ident: CR79 article-title: Prospects for the genetic analysis of schizophrenia publication-title: Schizophr Bull doi: 10.1093/schbul/15.3.365 – volume: 3 start-page: e303 year: 2013 ident: CR32 article-title: Expression of GABAA α2-, β1- and ɛ-receptors are altered significantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder publication-title: Transl Psychiatry doi: 10.1038/tp.2013.64 – volume: 117 start-page: 92 year: 2010 end-page: 98 ident: CR51 article-title: Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia publication-title: Schizophr Res doi: 10.1016/j.schres.2009.07.025 – volume: 10 start-page: 1569 year: 2009 end-page: 1578 ident: CR43 article-title: Adaptive regulation at the cell surface by -glycosylation publication-title: Traffic doi: 10.1111/j.1600-0854.2009.00981.x – volume: 62 start-page: 97 year: 2010 end-page: 135 ident: CR92 article-title: Regulation of GABA(A) receptor subunit expression by pharmacological agents publication-title: Pharmacol Rev doi: 10.1124/pr.109.002063 – volume: 25 start-page: 10469 year: 2005 end-page: 10478 ident: CR72 article-title: Gephyrin regulates the cell surface dynamics of synaptic GABAA receptors publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2267-05.2005 – volume: 2011 start-page: 723184 year: 2011 ident: CR1 article-title: GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia publication-title: Neural Plast doi: 10.1155/2011/723184 – volume: 77 start-page: 241 year: 2005 end-page: 252 ident: CR64 article-title: Variations in differential gene expression patterns across multiple brain regions in schizophrenia publication-title: Schizophr Res doi: 10.1016/j.schres.2005.03.020 – volume: 124 start-page: 200 year: 2013 end-page: 209 ident: CR91 article-title: Multiple tyrosine residues at the GABA binding pocket influence surface expression and mediate kinetics of the GABAA receptor publication-title: J Neurochem doi: 10.1111/jnc.12083 – volume: 168 start-page: 587 year: 2006 end-page: 590 ident: CR37 article-title: Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia publication-title: Exp Brain Res doi: 10.1007/s00221-005-0290-9 – volume: 1 start-page: 563 year: 1998 end-page: 571 ident: CR56 article-title: Postsynaptic clustering of major GABAA receptor subtypes requires the gamma 2 subunit and gephyrin publication-title: Nat Neurosci doi: 10.1038/2798 – volume: 57 start-page: 481 year: 2009 end-page: 495 ident: CR6 article-title: GABAA receptors and their associated proteins: Implications in the etiology and treatment of schizophrenia and related disorders publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2009.07.027 – volume: 28 start-page: 175 year: 1995 end-page: 179 ident: CR76 article-title: Cloning, sequence analysis and expression of two forms of mRNA coding for the human β 2 subunit of the GABA A receptor publication-title: Mol Brain Res doi: 10.1016/0169-328X(94)00228-7 – volume: 288 start-page: 21458 year: 2013 end-page: 21472 ident: CR85 article-title: Altered cortical GABAA receptor composition, physiology, and endocytosis in a mouse model of a human genetic absence epilepsy syndrome publication-title: J Biol Chem doi: 10.1074/jbc.M112.444372 – volume: 17 start-page: 6587 year: 1997 end-page: 6596 ident: CR94 article-title: Assembly of GABAA receptors composed of alpha1 and beta2 subunits in both cultured neurons and fibroblasts publication-title: J Neurosci doi: 10.1523/JNEUROSCI.17-17-06587.1997 – volume: 13 start-page: 147 year: 2008 end-page: 161 ident: CR15 article-title: Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4002011 – volume: 44 start-page: 673 year: 2010 end-page: 681 ident: CR31 article-title: Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2009.12.007 – volume: 581 start-page: 3658 year: 2007 end-page: 3664 ident: CR48 article-title: Glycoprotein folding and the role of EDEM1, EDEM2 and EDEM3 in degradation of folding-defective glycoproteins publication-title: FEBS Lett doi: 10.1016/j.febslet.2007.04.070 – volume: 93 start-page: 441 year: 1999 end-page: 448 ident: CR30 article-title: Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (hGAT-1) messenger RNA expression publication-title: Neuroscience doi: 10.1016/S0306-4522(99)00189-X – volume: 52 start-page: 155 year: 2006 end-page: 168 ident: CR4 article-title: Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology publication-title: Neuron doi: 10.1016/j.neuron.2006.09.020 – volume: 146 start-page: 177 year: 2013 end-page: 183 ident: CR49 article-title: Abnormal -linked glycosylation of cortical AMPA receptor subunits in schizophrenia publication-title: Schizophr Res doi: 10.1016/j.schres.2013.01.031 – volume: 55 start-page: 205 year: 1998 end-page: 211 ident: CR65 article-title: Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.55.3.205 – volume: 24 start-page: 688 year: 2013 end-page: 691 ident: CR50 article-title: -linked glycosylation of cortical -methyl-D-aspartate and kainate receptor subunits in schizophrenia publication-title: Neuroreport doi: 10.1097/WNR.0b013e328363bd8a – volume: 272 start-page: 1625 year: 2005 end-page: 1638 ident: CR42 article-title: The role of -glycosylation in the stability, trafficking and GABA-uptake of GABA-transporter 1. Terminal -glycans facilitate efficient GABA-uptake activity of the GABA transporter publication-title: FEBS J doi: 10.1111/j.1742-4658.2005.04595.x – volume: 285 start-page: 31348 year: 2010 end-page: 31361 ident: CR93 article-title: Glycosylation of β2 subunits regulates GABAA receptor biogenesis and channel gating publication-title: J Biol Chem doi: 10.1074/jbc.M110.151449 – volume: 7 start-page: e39190 year: 2012 ident: CR66 article-title: AMPA receptor subunit expression in the endoplasmic reticulum in frontal cortex of elderly patients with schizophrenia publication-title: PLoS One doi: 10.1371/journal.pone.0039190 – volume: 11 start-page: 2171 year: 2011 end-page: 2181 ident: CR90 article-title: Mass spectrometric analysis of GABAA receptor subtypes and phosphorylations from mouse hippocampus publication-title: Proteomics doi: 10.1002/pmic.201000374 – volume: 287 start-page: 27417 year: 2012 end-page: 27430 ident: CR86 article-title: γ-Aminobutyric acid type A (GABAA) receptor α subunits play a direct role in synaptic versus extrasynaptic targeting publication-title: J Biol Chem doi: 10.1074/jbc.M112.360461 – volume: 6 start-page: 312 year: 2005 end-page: 324 ident: CR2 article-title: Cortical inhibitory neurons and schizophrenia publication-title: Nat Rev Neurosci doi: 10.1038/nrn1648 – volume: 100 start-page: 279 year: 2007 end-page: 294 ident: CR95 article-title: GABAA receptor associated proteins: a key factor regulating GABAA receptor function publication-title: J Neurochem doi: 10.1111/j.1471-4159.2006.04206.x – volume: 153 start-page: 321 year: 1996 end-page: 330 ident: CR12 article-title: What are the functional consequences of neurocognitive deficits in schizophrenia? publication-title: Am J Psychiatry doi: 10.1176/ajp.153.3.321 – volume: 2 start-page: 795 year: 2002 end-page: 816 ident: CR52 article-title: Subunit composition, distribution and function of GABA(A) receptor subtypes publication-title: Curr Top Med Chem doi: 10.2174/1568026023393507 – start-page: 353 year: 2009 end-page: 381 ident: CR40 article-title: Auditory cortex anatomy and asymmetry in schizophrenia publication-title: Handbook of Neurochemistry and Molecular Neurobiology doi: 10.1007/978-0-387-30410-6_11 – volume: 47 start-page: 181 year: 1995 end-page: 234 ident: CR25 article-title: Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes publication-title: Pharmacol Rev – volume: 165 start-page: 1585 year: 2008 end-page: 1593 ident: CR59 article-title: Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2008.08030395 – volume: 40 start-page: 952 year: 2014 end-page: 957 ident: CR8 article-title: Early developmental disturbances of cortical inhibitory neurons: contribution to cognitive deficits in schizophrenia publication-title: Schizophr Bull doi: 10.1093/schbul/sbu111 – volume: 35 start-page: 57 year: 2012 end-page: 67 ident: CR3 article-title: Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia publication-title: Trends Neurosci doi: 10.1016/j.tins.2011.10.004 – volume: 38 start-page: 1910 year: 2013 end-page: 1920 ident: CR62 article-title: Dysfunction of the ubiquitin proteasome and ubiquitin-like systems in schizophrenia publication-title: Neuropsychopharmacology doi: 10.1038/npp.2013.84 – volume: 2011 start-page: bar009 year: 2011 ident: CR77 article-title: UniProt Knowledgebase: a hub of integrated protein data publication-title: Database (Oxford) doi: 10.1093/database/bar009 – volume: 57 start-page: 237 year: 2000 end-page: 245 ident: CR20 article-title: Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.57.3.237 – volume: 22 start-page: 2513 year: 2002 end-page: 2521 ident: CR88 article-title: Cell type- and input-specific differences in the number and subtypes of synaptic GABA(A) receptors in the hippocampus publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-07-02513.2002 – volume: 26 start-page: 251 year: 2002 end-page: 268 ident: CR55 article-title: Mechanisms of GABAA receptor assembly and trafficking publication-title: Mol Neurobiol doi: 10.1385/MN:26:2-3:251 – volume: 11 start-page: 1092 year: 2006 end-page: 1105 ident: CR82 article-title: Two isoforms of GABA(A) receptor beta2 subunit with different electrophysiological properties: differential expression and genotypical correlations in schizophrenia publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4001899 – volume: 28 start-page: 53 year: 2000 end-page: 67 ident: CR21 article-title: Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex publication-title: Neuron doi: 10.1016/S0896-6273(00)00085-4 – volume: 7 start-page: e36351 year: 2012 ident: CR33 article-title: Transcriptome sequencing revealed significant alteration of cortical promoter usage and splicing in schizophrenia publication-title: PLoS One doi: 10.1371/journal.pone.0036351 – volume: 36 start-page: 2103 year: 2011 end-page: 2110 ident: CR29 article-title: Selective pyramidal cell reduction of GABA(A) receptor α1 subunit messenger RNA expression in schizophrenia publication-title: Neuropsychopharmacology doi: 10.1038/npp.2011.102 – volume: 62 start-page: 1574 year: 2012 end-page: 1583 ident: CR5 article-title: GABAergic interneuron origin of schizophrenia pathophysiology publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2011.01.022 – volume: 7 start-page: e34586 year: 2012 ident: CR24 article-title: Complex control of GABA(A) receptor subunit mRNA expression: variation, covariation, and genetic regulation publication-title: PLoS One doi: 10.1371/journal.pone.0034586 – volume: 30 start-page: 497 year: 2010 end-page: 506 ident: CR45 article-title: Protein -glycosylation, protein folding, and protein quality control publication-title: Mol Cells doi: 10.1007/s10059-010-0159-z – volume: 69 start-page: 442 year: 2011 end-page: 449 ident: CR61 article-title: A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2010.09.052 – volume: 30 start-page: 497 year: 2010 ident: BFtp2015102_CR45 publication-title: Mol Cells doi: 10.1007/s10059-010-0159-z – volume: 7 start-page: e39190 year: 2012 ident: BFtp2015102_CR66 publication-title: PLoS One doi: 10.1371/journal.pone.0039190 – volume: 2011 start-page: 723184 year: 2011 ident: BFtp2015102_CR1 publication-title: Neural Plast doi: 10.1155/2011/723184 – volume: 44 start-page: 673 year: 2010 ident: BFtp2015102_CR31 publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2009.12.007 – volume: 3 start-page: e303 year: 2013 ident: BFtp2015102_CR32 publication-title: Transl Psychiatry doi: 10.1038/tp.2013.64 – volume: 10 start-page: 1569 year: 2009 ident: BFtp2015102_CR43 publication-title: Traffic doi: 10.1111/j.1600-0854.2009.00981.x – volume: 134 start-page: 260 year: 2012 ident: BFtp2015102_CR74 publication-title: Schizophr Res doi: 10.1016/j.schres.2011.11.029 – volume: 271 start-page: 89 year: 1996 ident: BFtp2015102_CR57 publication-title: J Biol Chem doi: 10.1074/jbc.271.1.89 – volume: 46 start-page: 616 year: 1999 ident: BFtp2015102_CR7 publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(99)00061-X – volume: 93 start-page: 441 year: 1999 ident: BFtp2015102_CR30 publication-title: Neuroscience doi: 10.1016/S0306-4522(99)00189-X – volume: 165 start-page: 479 year: 2008 ident: BFtp2015102_CR17 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2007.07081223 – start-page: 353 volume-title: Handbook of Neurochemistry and Molecular Neurobiology year: 2009 ident: BFtp2015102_CR40 doi: 10.1007/978-0-387-30410-6_11 – volume: 57 start-page: 1061 year: 2000 ident: BFtp2015102_CR14 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.57.11.1061 – volume: 285 start-page: 31348 year: 2010 ident: BFtp2015102_CR93 publication-title: J Biol Chem doi: 10.1074/jbc.M110.151449 – volume: 158 start-page: 1446 year: 2009 ident: BFtp2015102_CR68 publication-title: Neuroscience doi: 10.1016/j.neuroscience.2008.11.006 – volume: 57 start-page: 481 year: 2009 ident: BFtp2015102_CR6 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2009.07.027 – volume: 87 start-page: 9966 year: 1990 ident: BFtp2015102_CR27 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.87.24.9966 – volume: 7 start-page: e34586 year: 2012 ident: BFtp2015102_CR24 publication-title: PLoS One doi: 10.1371/journal.pone.0034586 – volume: 150 start-page: 1726 year: 1993 ident: BFtp2015102_CR63 publication-title: Am J Psychiatry doi: 10.1176/ajp.150.11.1726 – volume: 31 start-page: 11088 year: 2011 ident: BFtp2015102_CR18 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.1234-11.2011 – volume: 44 start-page: 1211 year: 1993 ident: BFtp2015102_CR89 publication-title: Mol Pharmacol doi: 10.1016/S0026-895X(25)13351-8 – volume: 165 start-page: 1594 year: 2008 ident: BFtp2015102_CR35 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2008.07121845 – volume: 38 start-page: 1910 year: 2013 ident: BFtp2015102_CR62 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2013.84 – volume: 34 start-page: 944 year: 2008 ident: BFtp2015102_CR22 publication-title: Schizophr Bull doi: 10.1093/schbul/sbn070 – volume: 4 start-page: e6977 year: 2009 ident: BFtp2015102_CR75 publication-title: PLoS One doi: 10.1371/journal.pone.0006977 – volume: 63 start-page: 465 year: 2008 ident: BFtp2015102_CR39 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2007.05.027 – volume: 28 start-page: 175 year: 1995 ident: BFtp2015102_CR76 publication-title: Mol Brain Res doi: 10.1016/0169-328X(94)00228-7 – volume: 5 start-page: e9547 year: 2010 ident: BFtp2015102_CR80 publication-title: PLoS One doi: 10.1371/journal.pone.0009547 – volume: 581 start-page: 3658 year: 2007 ident: BFtp2015102_CR48 publication-title: FEBS Lett doi: 10.1016/j.febslet.2007.04.070 – volume: 6 start-page: 23 year: 2012 ident: BFtp2015102_CR71 publication-title: Front Cell Neurosci doi: 10.3389/fncel.2012.00023 – volume: 116 start-page: 487 year: 2009 ident: BFtp2015102_CR70 publication-title: J Neural Transm doi: 10.1007/s00702-008-0143-3 – volume: 37 start-page: 1415 issue: Pt 6 year: 2009 ident: BFtp2015102_CR81 publication-title: Biochem Soc Trans doi: 10.1042/BST0371415 – volume: 162B start-page: 36 year: 2013 ident: BFtp2015102_CR38 publication-title: Am J Med Genet B Neuropsychiatr Genet doi: 10.1002/ajmg.b.32116 – volume: 590 start-page: 715 issue: Pt 4 year: 2012 ident: BFtp2015102_CR9 publication-title: J Physiol doi: 10.1113/jphysiol.2011.224659 – volume: 11 start-page: 2171 year: 2011 ident: BFtp2015102_CR90 publication-title: Proteomics doi: 10.1002/pmic.201000374 – volume: 336 start-page: 164 year: 1988 ident: BFtp2015102_CR78 publication-title: Nature doi: 10.1038/336164a0 – volume: 22 start-page: 2513 year: 2002 ident: BFtp2015102_CR88 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-07-02513.2002 – volume: 52 start-page: 258 year: 1995 ident: BFtp2015102_CR13 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1995.03950160008002 – volume: 168 start-page: 587 year: 2006 ident: BFtp2015102_CR37 publication-title: Exp Brain Res doi: 10.1007/s00221-005-0290-9 – volume: 146 start-page: 177 year: 2013 ident: BFtp2015102_CR49 publication-title: Schizophr Res doi: 10.1016/j.schres.2013.01.031 – volume: 91 start-page: 1009 year: 2011 ident: BFtp2015102_CR54 publication-title: Physiol Rev doi: 10.1152/physrev.00015.2010 – volume: 26 start-page: 251 year: 2002 ident: BFtp2015102_CR55 publication-title: Mol Neurobiol doi: 10.1385/MN:26:2-3:251 – volume: 62 start-page: 97 year: 2010 ident: BFtp2015102_CR92 publication-title: Pharmacol Rev doi: 10.1124/pr.109.002063 – volume: 10 start-page: 1074 year: 2005 ident: BFtp2015102_CR34 publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4001739 – volume: 104 start-page: 10164 year: 2007 ident: BFtp2015102_CR19 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0703806104 – volume: 13 start-page: 147 year: 2008 ident: BFtp2015102_CR15 publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4002011 – volume: 288 start-page: 21458 year: 2013 ident: BFtp2015102_CR85 publication-title: J Biol Chem doi: 10.1074/jbc.M112.444372 – volume: 287 start-page: 27417 year: 2012 ident: BFtp2015102_CR86 publication-title: J Biol Chem doi: 10.1074/jbc.M112.360461 – volume: 11 start-page: 1092 year: 2006 ident: BFtp2015102_CR82 publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4001899 – volume: 69 start-page: 442 year: 2011 ident: BFtp2015102_CR61 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2010.09.052 – volume: 25 start-page: 10469 year: 2005 ident: BFtp2015102_CR72 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2267-05.2005 – volume: 272 start-page: 1625 year: 2005 ident: BFtp2015102_CR42 publication-title: FEBS J doi: 10.1111/j.1742-4658.2005.04595.x – volume: 25 start-page: 594 year: 2005 ident: BFtp2015102_CR58 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.4011-04.2005 – volume: 15 start-page: 365 year: 1989 ident: BFtp2015102_CR79 publication-title: Schizophr Bull doi: 10.1093/schbul/15.3.365 – volume: 12 start-page: 43R year: 2002 ident: BFtp2015102_CR44 publication-title: Glycobiology doi: 10.1093/glycob/12.4.43R – volume: 57 start-page: 289 year: 1995 ident: BFtp2015102_CR73 publication-title: J R Stat Soc doi: 10.1111/j.2517-6161.1995.tb02031.x – volume: 88 start-page: 31 year: 2012 ident: BFtp2015102_CR47 publication-title: Proc Jpn Acad Ser B Phys Biol Sci doi: 10.2183/pjab.88.31 – volume: 17 start-page: 6587 year: 1997 ident: BFtp2015102_CR94 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.17-17-06587.1997 – volume: 9 start-page: 331 year: 2008 ident: BFtp2015102_CR53 publication-title: Nat Rev Neurosci doi: 10.1038/nrn2370 – volume: 36 start-page: 2103 year: 2011 ident: BFtp2015102_CR29 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2011.102 – volume: 35 start-page: 57 year: 2012 ident: BFtp2015102_CR3 publication-title: Trends Neurosci doi: 10.1016/j.tins.2011.10.004 – volume: 26 start-page: 119 year: 2000 ident: BFtp2015102_CR11 publication-title: Schizophr Bull doi: 10.1093/oxfordjournals.schbul.a033430 – volume: 31 start-page: 251 year: 2000 ident: BFtp2015102_CR10 publication-title: Brain Res Rev doi: 10.1016/S0165-0173(99)00041-7 – volume: 165 start-page: 1585 year: 2008 ident: BFtp2015102_CR59 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2008.08030395 – volume: 62 start-page: 1574 year: 2012 ident: BFtp2015102_CR5 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2011.01.022 – volume: 16 start-page: 557 year: 2011 ident: BFtp2015102_CR83 publication-title: Mol Psychiatry doi: 10.1038/mp.2010.47 – volume: 2011 start-page: bar009 year: 2011 ident: BFtp2015102_CR77 publication-title: Database (Oxford) doi: 10.1093/database/bar009 – volume: 12 start-page: 1063 year: 2002 ident: BFtp2015102_CR60 publication-title: Cereb Cortex doi: 10.1093/cercor/12.10.1063 – volume: 23 start-page: 6315 year: 2003 ident: BFtp2015102_CR16 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.23-15-06315.2003 – volume: 21 start-page: 999 year: 2011 ident: BFtp2015102_CR28 publication-title: Cereb Cortex doi: 10.1093/cercor/bhq169 – volume: 124 start-page: 200 year: 2013 ident: BFtp2015102_CR91 publication-title: J Neurochem doi: 10.1111/jnc.12083 – volume: 154 start-page: 1 year: 2014 ident: BFtp2015102_CR67 publication-title: Schizophr Res doi: 10.1016/j.schres.2014.01.028 – volume: 33 start-page: 543 year: 1999 ident: BFtp2015102_CR84 publication-title: J Psychiatr Res doi: 10.1016/S0022-3956(99)00039-4 – volume: 69 start-page: 69 year: 2000 ident: BFtp2015102_CR46 publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.69.1.69 – volume: 6 start-page: 312 year: 2005 ident: BFtp2015102_CR2 publication-title: Nat Rev Neurosci doi: 10.1038/nrn1648 – volume: 73 start-page: 1019 year: 2004 ident: BFtp2015102_CR41 publication-title: Annu Rev Biochem. doi: 10.1146/annurev.biochem.73.011303.073752 – volume: 1123 start-page: 1 year: 2006 ident: BFtp2015102_CR69 publication-title: Brain Res doi: 10.1016/j.brainres.2006.09.025 – volume: 28 start-page: 53 year: 2000 ident: BFtp2015102_CR21 publication-title: Neuron doi: 10.1016/S0896-6273(00)00085-4 – volume: 1 start-page: 563 year: 1998 ident: BFtp2015102_CR56 publication-title: Nat Neurosci doi: 10.1038/2798 – volume: 25 start-page: 1 year: 2001 ident: BFtp2015102_CR23 publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(01)00225-1 – volume: 39 start-page: 528 year: 2014 ident: BFtp2015102_CR36 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2013.190 – volume: 24 start-page: 688 year: 2013 ident: BFtp2015102_CR50 publication-title: Neuroreport doi: 10.1097/WNR.0b013e328363bd8a – volume: 77 start-page: 241 year: 2005 ident: BFtp2015102_CR64 publication-title: Schizophr Res doi: 10.1016/j.schres.2005.03.020 – volume: 47 start-page: 181 year: 1995 ident: BFtp2015102_CR25 publication-title: Pharmacol Rev doi: 10.1016/S0031-6997(25)06840-1 – volume: 7 start-page: e36351 year: 2012 ident: BFtp2015102_CR33 publication-title: PLoS One doi: 10.1371/journal.pone.0036351 – volume: 2 start-page: 795 year: 2002 ident: BFtp2015102_CR52 publication-title: Curr Top Med Chem doi: 10.2174/1568026023393507 – volume: 117 start-page: 92 year: 2010 ident: BFtp2015102_CR51 publication-title: Schizophr Res doi: 10.1016/j.schres.2009.07.025 – volume: 57 start-page: 237 year: 2000 ident: BFtp2015102_CR20 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.57.3.237 – volume: 56 start-page: 141 year: 2009 ident: BFtp2015102_CR87 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2008.07.045 – volume: 52 start-page: 155 year: 2006 ident: BFtp2015102_CR4 publication-title: Neuron doi: 10.1016/j.neuron.2006.09.020 – volume: 55 start-page: 205 year: 1998 ident: BFtp2015102_CR65 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.55.3.205 – volume: 19 start-page: 139 year: 1996 ident: BFtp2015102_CR26 publication-title: Trends Neurosci doi: 10.1016/S0166-2236(96)80023-3 – volume: 100 start-page: 279 year: 2007 ident: BFtp2015102_CR95 publication-title: J Neurochem doi: 10.1111/j.1471-4159.2006.04206.x – volume: 40 start-page: 952 year: 2014 ident: BFtp2015102_CR8 publication-title: Schizophr Bull doi: 10.1093/schbul/sbu111 – volume: 153 start-page: 321 year: 1996 ident: BFtp2015102_CR12 publication-title: Am J Psychiatry doi: 10.1176/ajp.153.3.321 – reference: 21742794 - Physiol Rev. 2011 Jul;91(3):1009-22 – reference: 20221451 - PLoS One. 2010;5(3):e9547 – reference: 17689500 - Biol Psychiatry. 2008 Mar 1;63(5):465-74 – reference: 17471287 - Mol Psychiatry. 2008 Feb;13(2):147-61 – reference: 8550630 - J Biol Chem. 1996 Jan 5;271(1):89-96 – reference: 2903449 - Nature. 1988 Nov 10;336(6195):164-7 – reference: 22615685 - Front Cell Neurosci. 2012 May 15;6:23 – reference: 20100621 - J Psychiatr Res. 2010 Jul;44(10):673-81 – reference: 20123953 - Pharmacol Rev. 2010 Mar;62(1):97-135 – reference: 10628531 - J Psychiatr Res. 1999 Nov-Dec;33(6):543-8 – reference: 10472415 - Biol Psychiatry. 1999 Sep 1;46(5):616-26 – reference: 12428759 - Mol Neurobiol. 2002 Oct-Dec;26(2-3):251-68 – reference: 19716271 - Schizophr Res. 2010 Mar;117(1):92-8 – reference: 17015233 - Neuron. 2006 Oct 5;52(1):155-68 – reference: 23744069 - J Biol Chem. 2013 Jul 19;288(29):21458-72 – reference: 22154068 - Trends Neurosci. 2012 Jan;35(1):57-67 – reference: 16280585 - J Neurosci. 2005 Nov 9;25(45):10469-78 – reference: 15803162 - Nat Rev Neurosci. 2005 Apr;6(4):312-24 – reference: 21447597 - Database (Oxford). 2011;2011:bar009 – reference: 19139805 - J Neural Transm (Vienna). 2009 Apr;116(4):487-91 – reference: 7707873 - Brain Res Mol Brain Res. 1995 Jan;28(1):175-9 – reference: 23121119 - J Neurochem. 2013 Jan;124(2):200-9 – reference: 21340671 - Mol Cells. 2010 Dec;30(6):497-506 – reference: 22314014 - Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(2):31-40 – reference: 2683037 - Schizophr Bull. 1989;15(3):365-72 – reference: 22506031 - PLoS One. 2012;7(4):e34586 – reference: 11086983 - Neuron. 2000 Oct;28(1):53-67 – reference: 18382465 - Nat Rev Neurosci. 2008 May;9(5):331-43 – reference: 19041929 - Neuroscience. 2009 Feb 18;158(4):1446-59 – reference: 9510214 - Arch Gen Psychiatry. 1998 Mar;55(3):205-11 – reference: 15923110 - Schizophr Res. 2005 Sep 15;77(2-3):241-52 – reference: 22206711 - Schizophr Res. 2012 Feb;134(2-3):260-6 – reference: 8214183 - Am J Psychiatry. 1993 Nov;150(11):1726-7 – reference: 23462048 - Schizophr Res. 2013 May;146(1-3):177-83 – reference: 10465426 - Neuroscience. 1999;93(2):441-8 – reference: 9254671 - J Neurosci. 1997 Sep 1;17(17):6587-96 – reference: 17083446 - J Neurochem. 2007 Jan;100(2):279-94 – reference: 21795557 - J Neurosci. 2011 Jul 27;31(30):11088-95 – reference: 18923069 - Am J Psychiatry. 2008 Dec;165(12):1594-603 – reference: 21677653 - Neuropsychopharmacology. 2011 Sep;36(10):2103-10 – reference: 16172613 - Mol Psychiatry. 2005 Dec;10(12):1074-88, 1057 – reference: 15659595 - J Neurosci. 2005 Jan 19;25(3):594-603 – reference: 20639197 - J Biol Chem. 2010 Oct 8;285(41):31348-61 – reference: 17045977 - Brain Res. 2006 Dec 6;1123(1):1-11 – reference: 12217970 - Cereb Cortex. 2002 Oct;12(10):1063-70 – reference: 8658597 - Trends Neurosci. 1996 Apr;19(4):139-43 – reference: 17553960 - Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10164-9 – reference: 18760291 - Neuropharmacology. 2009 Jan;56(1):141-8 – reference: 22558445 - PLoS One. 2012;7(4):e36351 – reference: 19763268 - PLoS One. 2009;4(9):e6977 – reference: 23917429 - Neuropsychopharmacology. 2014 Feb;39(3):528-37 – reference: 15189166 - Annu Rev Biochem. 2004;73:1019-49 – reference: 10755673 - Schizophr Bull. 2000;26(1):119-36 – reference: 11377916 - Neuropsychopharmacology. 2001 Jul;25(1):1-27 – reference: 1702226 - Proc Natl Acad Sci U S A. 1990 Dec;87(24):9966-70 – reference: 24560881 - Schizophr Res. 2014 Apr;154(1-3):1-13 – reference: 21277876 - Neuropharmacology. 2012 Mar;62(3):1574-83 – reference: 21538884 - Proteomics. 2011 Jun;11(11):2171-81 – reference: 11074872 - Arch Gen Psychiatry. 2000 Nov;57(11):1061-9 – reference: 7702443 - Arch Gen Psychiatry. 1995 Apr;52(4):258-66 – reference: 24022508 - Transl Psychiatry. 2013;3:e303 – reference: 10196563 - Nat Neurosci. 1998 Nov;1(7):563-71 – reference: 22219337 - J Physiol. 2012 Feb 15;590(4):715-24 – reference: 16362364 - Exp Brain Res. 2006 Jan;168(4):587-90 – reference: 11923416 - J Neurosci. 2002 Apr 1;22(7):2513-21 – reference: 19631671 - Neuropharmacology. 2009 Oct-Nov;57(5-6):481-95 – reference: 15794750 - FEBS J. 2005 Apr;272(7):1625-38 – reference: 12867516 - J Neurosci. 2003 Jul 16;23(15):6315-26 – reference: 12171572 - Curr Top Med Chem. 2002 Aug;2(8):795-816 – reference: 17499246 - FEBS Lett. 2007 Jul 31;581(19):3658-64 – reference: 25053651 - Schizophr Bull. 2014 Sep;40(5):952-7 – reference: 23571678 - Neuropsychopharmacology. 2013 Sep;38(10):1910-20 – reference: 10711910 - Arch Gen Psychiatry. 2000 Mar;57(3):237-45 – reference: 19761541 - Traffic. 2009 Nov;10(11):1569-78 – reference: 18586694 - Schizophr Bull. 2008 Sep;34(5):944-61 – reference: 10966453 - Annu Rev Biochem. 2000;69:69-93 – reference: 16983389 - Mol Psychiatry. 2006 Dec;11(12):1092-105 – reference: 8610818 - Am J Psychiatry. 1996 Mar;153(3):321-30 – reference: 18281411 - Am J Psychiatry. 2008 Apr;165(4):479-89 – reference: 12042244 - Glycobiology. 2002 Apr;12(4):43R-56R – reference: 22720072 - PLoS One. 2012;7(6):e39190 – reference: 23820740 - Neuroreport. 2013 Aug 21;24(12):688-91 – reference: 21904685 - Neural Plast. 2011;2011:723184 – reference: 10719152 - Brain Res Brain Res Rev. 2000 Mar;31(2-3):251-69 – reference: 20404824 - Mol Psychiatry. 2011 May;16(5):557-68 – reference: 22711532 - J Biol Chem. 2012 Aug 10;287(33):27417-30 – reference: 19909288 - Biochem Soc Trans. 2009 Dec;37(Pt 6):1415-8 – reference: 20843900 - Cereb Cortex. 2011 May;21(5):999-1011 – reference: 21145041 - Biol Psychiatry. 2011 Mar 1;69(5):442-9 – reference: 7568326 - Pharmacol Rev. 1995 Jun;47(2):181-234 – reference: 18923067 - Am J Psychiatry. 2008 Dec;165(12):1585-93 – reference: 23169775 - Am J Med Genet B Neuropsychiatr Genet. 2013 Jan;162B(1):36-43 – reference: 8264558 - Mol Pharmacol. 1993 Dec;44(6):1211-8 |
SSID | ssj0000548171 |
Score | 2.0284023 |
Snippet | Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA
A
R). In schizophrenia,... Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA A R). In schizophrenia,... Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABA(A)R). In schizophrenia,... Inhibitory neurotransmission is primarily mediated by γ-aminobutyric acid (GABA) activating synaptic GABA type A receptors (GABAA R). In schizophrenia,... |
SourceID | pubmedcentral proquest pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | e612 |
SubjectTerms | 101/28 631/378/340 692/699/476/1799 82 82/29 82/80 Aged Behavioral Sciences Biological Psychology Blotting, Western Brain - metabolism Brain - physiopathology Case-Control Studies Endoplasmic Reticulum - chemistry Female Glycosylation Humans Male Medicine Medicine & Public Health Neurosciences Original original-article Pharmacotherapy Psychiatry Receptors, GABA-A - analysis Receptors, GABA-A - metabolism Receptors, GABA-A - physiology Receptors, GABA-B - metabolism Receptors, GABA-B - physiology Schizophrenia - metabolism Schizophrenia - physiopathology Subcellular Fractions - chemistry Synapses - chemistry Temporal Lobe - chemistry |
SummonAdditionalLinks | – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dS8MwEA-6gfgifludEmG-CMWlSdv0sYpzDObLHOytJGmCA-mG3f5_c21WNueDby25tMddkrvkLr9DqJvzXqCNYL4OpfIZj4wviWS-EtYeRTw03MDd4dF7NJiw4TScOpzt0qVV1pCW1TK9zg57WgK2JAkBaWAftQGj3Q7qdpoOx8PmSMV6H5zExN3C61G-2Wvb7uw4k7s5kb8Co5W96R-jI-co4rRm7QTt6eIUHYxcKPwMjVNZgL_5hcuVhON3yCfFlWlyVyvx3OC39DlNsV3V9MJuroF0ZedwiWcFLjfT7bCEUhHnaNJ__XgZ-K5Cgq9oGAe-SJTKTaIDkYeW80ALiOtFkRUDZ5SamAraM8KAU2NozuNYM7sHySnRMQmIpBeoVcwLfYWwUtRO3ySRVnlMhlRoIhIOaDZMaW60hx7X8suUgw-HKhZfWRXGpjxbLjIQtn0JPNRtiBc1asbfZJ21IjI3dcoM8FIBA4j0PHTfNNtBD6IUhZ6vgAZqi8Z2ufHQZa235j9BBKHC0PaOtzTaEACg9nZLMfusgLUraB345sNa9xts7bJ__U-6G3QIj1XaIOug1vJ7pW-tK7OUd24I_wBTr_PX priority: 102 providerName: Springer Nature |
Title | Abnormal subcellular localization of GABAA receptor subunits in schizophrenia brain |
URI | https://link.springer.com/article/10.1038/tp.2015.102 https://www.ncbi.nlm.nih.gov/pubmed/26241350 https://www.proquest.com/docview/1791131110 https://www.proquest.com/docview/1702087257 https://pubmed.ncbi.nlm.nih.gov/PMC4564557 |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED-2FsZexr6XrQsadC8D08iSLflpuKFdCbSMdYW8GUmWWKE42Zz8_7tTFK9Zxp6MrbMtdLrT6e70O4DjVk9yH4zMfGFdJnUZMsutzJzB9ajURdCBzg5fXpUXN3I2L-bJ4dantMqtToyKul048pGfEIwmQcPwyeflz4yqRlF0NZXQeAiHBF1Gs1rN1eBjQXNEc8XTsbyJ0CcrgqjkBQEW7C5Ee9blfpLkX5HSuACdP4UnyXJk9YbVz-CB757Do8sUG38B17XtyAC9Y_3akj-eEkxZXKvSWUu2COxLfVrXDNWcX-Jum0jXKNQ9u-1Yfz__jlmqHfESbs7Pvk8vslQyIXOiUHlmKufaUPnctAX2PPeGAn1licOgpRBBCSMmwQSycoJotVJe4qakFdwrnnMrXsFBt-j8G2DOCZTnqrLITWkLYTw3lSZ4G-m8Dn4En7bj17iEJ05lLe6aGNcWulktGxpsvMlHcDwQLzcwGv8mO9oyokmy1Dd_OD-CD0MzSgENpen8Yk00VGxUof4ZwesN34b_5CXFDgt8W-1wdCAghO3dlu72R0Tajlg79M2PW97f69Z-99_-v_vv4DFRxvRBeQQHq19r_x5NmpUdx3k7hsO6nl3P8Hp6dvX1Gz6dltNxdBP8Bmcq_DI |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgEXxJuFAkZqL0hRE9uJnQNC4VG2tNsLrbS3YDu2qFRlF7IrxJ_iNzKTTUKXRdx6jDx2LM94ZuwZfwOwW-mY-2Bk5FPrIqmzENnEysgZtEeZToMO9HZ4cpKNz-SnaTrdgl_9WxhKq-x1Yquoq5mjO_J9gtEkaJgkfjP_FlHVKIqu9iU0VmJx5H_-wCNb8_rwPfJ3j_ODD6fvxlFXVSByIlU8MrlzVcg9N1VaOc-9oVhYlulEaSlEUMKIOJhAjkAQlVbKS_TbK5F4lfDEChz3GlxHwxvTYU9N1XCng-4PjpJ0zwBjofcXBImZpASQsG74NrzZzaTMvyKzrcE7uAO3O0-VFSvRugtbvr4HNyZdLP4-fC5sTQ7vBWuWlu7_KaGVtbaxe9vJZoF9LN4WBUO16ud4uifSJSqRhp3XrLmc78cs1ap4AGdXspgPYbue1f4xMOcE6o88tyg90qbC-MTkmuB0pPM6-BG86tevdB1-OZXRuCjbOLrQ5WJe0mLjBx_B7kA8X8F2_Jtsp2dE2e3dpvwjaSN4OTTjrqOlNLWfLYmGipsq1HcjeLTi2_AfnlGsMsXeao2jAwEheq-31OdfW2TvFtuHxtzreX9pWpvTf_L_6b-Am-PTyXF5fHhy9BRuUa82dVHuwPbi-9I_Q3dqYZ-3Mszgy1Vvmt8cqjNW |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwED-NTpp4QYy_hQ2MtL0gRa3tJHYe0JSxlY2xagIm7S2zHVtMmtJCWiG-Gp9uvtQJK0W87THy2bHuzuez7_w7gJ1SDpl1Ko5sok0Uy9RFmuo4MsrvR6lMnHT4dvh0nB6dxx8vkos1-N2-hcG0ytYmNoa6nBi8Ix8gjCZCw9DhwIW0iLOD0d70e4QVpDDS2pbTWKjIif310x_f6nfHB17Wu4yNDr--P4pChYHI8ESwSGXGlC6zTJVJaSyzCuNiaSqpkDHnTnDFh045dAocL6UQNvY-fMmpFZRRzf2492Bd4KmoB-v7h-Ozz90Nj3eG_Dg0PAoccjmYIUAmTRAuYXkbXPFtV1M0_4rTNtvf6CE8CH4ryReKtglrtnoEG6chMv8YvuS6Qvf3mtRzjdEATG8lzU4ZXnqSiSMf8v08J97I2qk_6yPp3JuUmlxVpL6d_Uc0Vq54Aud3ws6n0KsmlX0OxBjurUmWaa9LsU64slRlEsF1YmOls3142_KvMAHNHItqXBdNVJ3LYjYtkNn-g_VhpyOeLkA8_k221QqiCCu5Lv7oXR_edM1-DSIrVWUnc6TBUqfCW78-PFvIrfsPSzFymfjeYkmiHQHiey-3VFffGpzvBukHx9xtZX9rWqvTf_H_6b-GDb9gik_H45OXcB87NXmM8Rb0Zj_mdtv7VjP9Kigxgcu7Xjc3j3A48Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abnormal+subcellular+localization+of+GABAA+receptor+subunits+in+schizophrenia+brain&rft.jtitle=Translational+psychiatry&rft.au=Mueller%2C+T+M&rft.au=Remedies%2C+C+E&rft.au=Haroutunian%2C+V&rft.au=Meador-Woodruff%2C+J+H&rft.date=2015-08-04&rft.issn=2158-3188&rft.eissn=2158-3188&rft.volume=5&rft.spage=e612&rft_id=info:doi/10.1038%2Ftp.2015.102&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2158-3188&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2158-3188&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2158-3188&client=summon |